The endothelial-protective effects of HMG-CoA reductase inhibition in the setting of ischemia and reperfusion injury

Clinical Hemorheology and Microcirculation

Volumn 45, Issue 2-4, 2010, Pages 161-167

  Liuni, Andrew ^a   Luca, Mary Clare ^a   Gori, Tommaso ^b   Parker, John D ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Endothelium; ischemia; ischemic preconditioning; reperfusion; statins

Indexed keywords

CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE;

CORONARY ARTERY BYPASS GRAFT; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; HEART PROTECTION; HUMAN; ISCHEMIA; ISCHEMIC PRECONDITIONING; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION INJURY; REVIEW; VASCULAR ENDOTHELIUM;

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; ENDOTHELIUM, VASCULAR; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIA; PROTECTIVE AGENTS; PYRIMIDINES; REPERFUSION INJURY; SULFONAMIDES;

EID: 77957274427     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: 10.3233/CH-2010-1294     Document Type: Review

References (52)

1. H.D. Aronow, E.J. Topol, M.T. Roe, P.L. Houghtaling, K.E. Wolski, A.M. Lincoff, R.A. Harrington, R.M. Califf, E.M. Ohman, N.S. Kleiman, M.Keltai, R.G.Wilcox, A.Vahanian, P.W. Armstrong and M.S. Lauer, Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study, Lancet 357 (2001), 1063-1068. (Pubitemid 32322536)
2. S. Atar, Y. Ye, Y. Lin, S.Y. Freeberg, S.P. Nishi, S. Rosanio, M.H. Huang, B.F. Uretsky, J.R. Perez-Polo and Y. Birnbaum, Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2, Am J Physiol Heart Circ Physiol 290 (2006), H1960-H1968.
3. N. Bao, S. Minatoguchi, H. Kobayashi, S. Yasuda, I. Kawamura, M. Iwasa, T. Yamaki, S. Sumi, Y. Misao, M. Arai, K. Nishigaki, G. Takemura, T. Fujiwara and H. Fujiwara, Pravastatin reduces myocardial infarct size via increasing protein kinase C-dependent nitric oxide, decreasing oxyradicals and opening the mitochondrial adenosine triphosphate-sensitive potassium channels in rabbits, Circ J 71 (2007), 1622-1628. (Pubitemid 47529667)
4. G. Bartoli, G. Menegaz, Lisi M. , Di Stolfo G. , Dragoni S. and Gori T., Model-based analysis of flow-mediated dilation and intima-media thickness, Int J Biomed Imaging 2008 (2008), 738-1545
5. Y. Birnbaum, T. Ashitkov, B.F. Uretsky, S. Ballinger and M. Motamedi, Reduction of infarct size by short-term pretreatment with atorvastatin, Cardiovasc Drugs Ther 17 (2003), 25-30. (Pubitemid 36898095)
6. Y. Birnbaum,Y. Lin,Y.Ye, R. Merla, J.R. Perez-Polo and B.F. Uretsky, Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat, J Cardiovasc Pharmacol Ther 13 (2008), 72-79. (Pubitemid 351246258)
7. Y. Birnbaum, Y. Ye, S. Rosanio, S. Tavackoli, Z.Y. Hu, E.R. Schwarz and B.F. Uretsky, Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury, Cardiovasc Res 65 (2005), 345-355. (Pubitemid 40082476)
8. R.S. Bresalier, R.S. Sandler, H. Quan, Bolognese J.A. , Oxenius B. , Horgan K. , Lines C., Riddell R. , D. Morton, A. Lanas, M.A. Konstam and J.A. Baron, Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial, N Engl J Med 352 (2005), 1092-1102. (Pubitemid 40365350)
9. C. Briguori, A. Colombo, F. Airoldi, A. Violante, A. Focaccio, P. Balestrieri, E.P. Paolo, B. Golia, S. Lepore, G. Riviezzo, P. Scarpato, M. Librera, E. Bonizzoni and B. Ricciardelli, Statin administration before percutaneous coronary intervention: Impact on periprocedural myocardial infarction, Eur Heart J 25 (2004), 1822-1828. (Pubitemid 39330233)
10. J.W. Calvert and D.J. Lefer, Statin therapy and myocardial no-reflow, Br J Pharmacol 149 (2006), 229-231.
11. A.W. Chan, D.L. Bhatt, D.P. Chew, M.J. Quinn, D.J. Moliterno, E.J. Topol and S.G, Ellis, Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention, Circulation 105 (2002), 691-696.
12. S.M. Chang, N. Yazbek and N.M. Lakkis, Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome, Catheter Cardiovasc Interv 62 (2004), 193-197. (Pubitemid 38788696)
13. M.I. Dotani, D.M. Elnicki, A.C. Jain and C.M. Gibson, Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting, Am J Cardiol 86 (2000), 1128-1130, A1126.
14. J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, A. Langendorfer, E.A. Stein, W. Kruyer and A.M. Gotto, Jr, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study, JAMA 279 (1998), 1615-1622. (Pubitemid 28248586)
15. Gori T., Di Stolfo G. , Dragoni S., Lisi M. , M.C. Leone, S. Forconi and Parker J.D., The mechanism of nitrate-induced preconditioning, Clin Hemorheol Microcirc 39 (2008), 191-196. (Pubitemid 352039996)
16. Gori T., Di Stolfo G. , S. Sicuro, Dragoni S., Lisi M. , S. Forconi and Parker J.D., Nitroglycerin protects the endothelium from ischaemia and reperfusion: Human mechanistic insight, Br J Clin Pharmacol 64 (2007), 145-150. (Pubitemid 47063243)
17. Gori T., Dragoni S., Lisi M. , Di Stolfo G. , Sonnati S., Fineschi M. and Parker J.D., Conduit artery constriction mediated by low flow a novel noninvasive method for the assessment of vascular function, J Am Coll Cardiol 51 (2008), 1953-1958. (Pubitemid 351636451)
18. Gori T., S. Sicuro, Dragoni S., G. Donati, S. Forconi and Parker J.D., Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: A human in vivo study, Circulation 111 (2005), 742-746. (Pubitemid 40250634)
19. S. Grotti and Gori T., Endothelium, ischemia and the good side of oxygen free radicals, Clin Hemorheol Microcirc 39 (2008), 197-203. (Pubitemid 352039997)
20. T. Habon, B. Horvath, L. Szapary and K. Toth, Short-term effects of atorvastatin on hemorheologic parameters and endothelial dysfunction in patients with hypercholesterolemia, Lower is better? Clin Hemorheol Microcirc 40 (2008), 325-326.
21. J. Herrmann, A. Lerman, D. Baumgart, L. Volbracht, R. Schulz, B.C. von, M. Haude, G. Heusch and R. Erbel, Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction, Circulation 106 (2002), 2180-2183. (Pubitemid 35222209)
22. Y. Ikeda, L.H. Young and A.M. Lefer, Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats, J Cardiovasc Pharmacol 41 (2003), 649-656. (Pubitemid 36373804)
23. S.P. Jones, M.F. Gibson, D.M. Rimmer, T.M. Gibson, B.R. Sharp and D.J. Lefer. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor, J Am Coll Cardiol 40 (2002), 1172-1178.
24. P. Juni, L. Nartey, S. Reichenbach, R. Sterchi, P.A. Dieppe and M. Egger, Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis, Lancet 364 (2004), 2021-2029. (Pubitemid 39593078)
25. P.M. Kearney, C. Baigent, J. Godwin, H. Halls, J.R. Emberson and C. Patrono, Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials, BMJ 332 (2006), 1302-1308. (Pubitemid 44365384)
26. R.K. Kharbanda, M. Peters, B.Walton, M. Kattenhorn, M. Mullen, N. Klein, P. Vallance, J. Deanfield and R. MacAllister, Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo, Circulation 103 (2001), 1624-1630. (Pubitemid 32246608)
27. D.J. Lefer, R. Scalia, S.P. Jones, B.R. Sharp, M.R. Hoffmeyer, A.R. Farvid, M.F. Gibson and A.M. Lefer, HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury, FASEB Journal 15 (2001), 1454-1456.
28. J.K. Liao and U. Laufs, Pleiotropic effects of statins, Annu Rev Pharmacol Toxicol 45 (2005), 89-118. (Pubitemid 40261799)
29. A. Liuni, M.C. Luca, Gori T. and Parker J.D., Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism, J Am Coll Cardiol 55(10) (2010), 1002-1006.
30. V.A. Mannacio, D. Iorio, A.V. De, L.F. Di and F. Musumeci, Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: A randomized trial, J Thorac Cardiovasc Surg 136 (2008), 1541-1548.
31. A. Marossy, P. Svorc, I. Kron , S. Gresova, Hemorheology and circulation, Clin Hemorheol Microcirc 42 (2009), 239-258.
32. K. Matschke, F. Jung, Regulation of the myocardial microcirculation, Clin Hemorheol Microcirc 39 (2008), 265-279. (Pubitemid 352040008)
33. R. Merla, I.N. Daher, Y. Ye, B.F. Uretsky and Y. Birnbaum, Pretreatment with statins may reduce cardiovascular morbidity and mortality after elective surgery and percutaneous coronary intervention: Clinical evidence and possible underlying mechanisms, Am Heart J 154 (2007), 391-402. (Pubitemid 47071895)
34. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: A randomised placebo-controlled trial, Lancet 360 (2002), 7-22. (Pubitemid 34756487)
35. S.R. Mulukutla, O.C. Marroquin, C. Smith, R. Varghese, W.D. Anderson, J.S. Lee, H.A. Cohen, P.J. Counihan, A.B. Lee, V. Gulati and D. McNamara, Effect of statin therapy prior to elective percutaneous coronary intervention on frequency of periprocedural myocardial injury, Am J Cardiol 94 (2004), 1363-1366. (Pubitemid 39556203)
36. N.A. Nussmeier, A.A. Whelton, M.T. Brown, R.M. Langford, A. Hoeft, J.L. Parlow, S.W. Boyce and K.M. Verburg, Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery, N Engl J Med 352 (2005), 1081-1091. (Pubitemid 40365349)
37. W. Pan, T. Pintar, J. Anton, V.V. Lee, W.K. Vaughn and C.D. Collard, Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery, Circulation 110 (2004), II45-II49. (Pubitemid 39263697)
38. V. Pasceri, G. Patti, A. Nusca, C. Pristipino, G. Richichi and S.G. Di, Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study, Circulation 110 (2004), 674-678. (Pubitemid 39056265)
39. D.A. Pascual, J.M. Arribas, P.L. Tornel, F. Marin, C. Oliver, M. Ahumada, J. Gomez-Plana, P. Martinez, R. Arcas and M. Valdes, Preoperative statin therapy and troponin T predict early complications of coronary artery surgery, Ann Thorac Surg 81 (2006), 78-83. (Pubitemid 41815377)
40. G. Patti, V. Pasceri, G. Colonna, M. Miglionico, D. Fischetti, G. Sardella, A. Montinaro and G. Di Sciascio, Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: Results of the ARMYDA-ACS randomized trial, J Am Coll Cardiol 49 (2007), 1272-1278. (Pubitemid 46467240)
41. T.R. Pedersen, O. Faergeman, J.J. Kastelein, A.G. Olsson, M.J. Tikkanen, I. Holme, M.L. Larsen, F.S. Bendiksen, C. Lindahl, M. Szarek and J. Tsai, High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial, JAMA 294 (2005), 2437-2445. (Pubitemid 41627921)
42. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, N Engl J Med 339 (1998), 1349-1357.
43. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S), Lancet 344 (1994), 1383-1389.
44. Y. Rikitake and J.K. Liao, Rho GTPases, statins, and nitric oxide, Circ Res 97 (2005), 1232-1235. (Pubitemid 43755179)
45. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, L. Brown, J.W. Warnica, J.M. Arnold, C.C. Wun, B.R. Davis and E. Braunwald, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators, N Engl J Med 335 (1996), 1001-1009. (Pubitemid 26338729)
46. R. Scalia, M.E. Gooszen, S.P. Jones, M. Hoffmeyer, D.M. Rimmer, S.D. Trocha, P.L. Huang, M.B. Smith, A.M. Lefer and D.J. Lefer, Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice, Circulation 103 (2001), 2598-2603. (Pubitemid 32521971)
47. J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, P.W. MacFarlane, J.H. McKillop and C.J. Packard, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.West of Scotland Coronary Prevention Study Group, N Engl J Med 333 (1995), 1301-1307.
48. S.D. Solomon, J.J. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, P. Finn, W.F. Anderson, A. Zauber, E. Hawk and M. Bertagnolli, Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention, N Engl J Med 352 (2005), 1071-1080. (Pubitemid 40365348)
49. M. Uyuklu, H.J. Meiselman and O.K. Baskurt, Effect of decreased plasma cholesterol by atorvastatin treatment on erythrocyte mechanical properties, Clin Hemorheol Microcirc 36 (2007), 25-33. (Pubitemid 46067267)
50. D.H. Walter, S. Fichtlscherer, M.B. Britten, P. Rosin, W. Auch-Schwelk, V. Schachinger and A.M. Zeiher, Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation, J Am Coll Cardiol 38 (2001), 2006-2012. (Pubitemid 33116578)
51. Y. Ye, J.D. Martinez, R.J. Perez-Polo, Y. Lin, B.F. Uretsky and Y. Birnbaum, The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin, Am J Physiol Heart Circ Physiol 295 (2008), H343-H351.
52. J.L. Zhao, Y.J. Yang, C.J. Cui, S.J. You and R.L. Gao, Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel, Br J Pharmacol 149 (2006), 243-249.